SCHEMBL1736698

SCHEMBL1736698

NC(=NCCC[C@H](N)C(=O)O)NO

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 9/20 0.68
CYP2C19 P33261 3/20 0.68
CYP1A2 P05177 2/20 0.68
TSHR P16473 2/20 0.68
GLA P06280 1/20 0.68
NFKB1 P19838 1/20 0.68
APEX1 P27695 1/20 0.68
NOS1 P29475 10/20 0.64
NOS3 P29474 6/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
DDAH1 O94760 5/20 0.60
THPO P40225 1/20 0.58
CYP3A4 P08684 1/20 0.57
BLM P54132 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1736695 1.00 NOS2 (0.68) NOS2CYP2C19CYP1A2TSHRGLA
Acetic Acid SCHEMBL29386173 0.95 NOS2 (0.68) NOS2CYP2C19CYP1A2TSHRGLA
Nor-Noha SCHEMBL29414881 0.89 NOS2 (0.52) NOS2CYP2C19CYP1A2TSHRGLA
Nor-Noha SCHEMBL29499929 0.89 NOS2 (0.52) NOS2CYP2C19CYP1A2TSHRGLA
Tilarginine SCHEMBL23099403 0.86 NOS1 (0.69) NOS2CYP2C19CYP1A2TSHRGLA
SCHEMBL29824834 0.86 NOS2 (0.68) NOS2CYP2C19CYP1A2TSHRGLA
Nor-Noha SCHEMBL30600976 0.84 NOS2 (0.53) NOS2CYP2C19CYP1A2TSHRGLA
SCHEMBL29364827 0.83 NOS2 (0.64) NOS2CYP2C19CYP1A2TSHRGLA
Arginine SCHEMBL288993 0.81 NOS2 (1.00) NOS2CYP2C19CYP1A2TSHRGLA
Arginine SCHEMBL43261 0.81 NOS2 (1.00) NOS2CYP2C19CYP1A2TSHRGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118742325-A Methods for preventing or treating diseases or conditions associated with antineoplastic agents 上海岸阔医药科技有限公司 2024-10-01 CN claimed
US-11779634-B2 Fungal iron acquisition inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2023-10-10 US claimed
US-20220211820-A1 FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF UNIV CASE WESTERN RESERVE (US) 2022-07-07 US claimed
US-11229685-B2 Fungal iron acquisition inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2022-01-25 US claimed
EP-4734770-A1 COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME Mars, Incorporated (US) 2026-05-06 EP disclosed
CN-118812651-B Novel non-ribosomal antifungal peptide MaAFP as well as preparation method and application thereof 重庆大学 2025-02-14 CN disclosed
CN-118716538-B Litopenaeus vannamei feed and preparation method thereof 广东海洋大学 2025-02-14 CN disclosed
WO-2025006362-A1 COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME MARS, INCORPORATED (US) 2025-01-02 WO disclosed
CN-118812651-A Novel non-ribosomal antifungal peptide MaAFP as well as preparation method and application thereof 重庆大学 2024-10-22 CN disclosed
CN-118716538-A Litopenaeus vannamei feed and preparation method thereof 广东海洋大学 2024-10-01 CN disclosed
EP-4376886-A2 METHODS OF TREATING CANCER Foghorn Therapeutics Inc. (US) 2024-06-05 EP disclosed
US-11779634-B2 Fungal iron acquisition inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2023-10-10 US disclosed
EP-3042718-A1 DEVICE FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION Dietz, Ulrich (DE) 2016-07-13 EP disclosed
US-20160122686-A1 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2016-05-05 US disclosed
EP-2585420-B1 METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2016-04-06 EP disclosed
US-9127233-B2 Device and method for solubilizing, separating, removing and reacting carboxylic acids in oils, fats, aqueous or organic solutions by means of micro-or nanoemulsification Dietz, Ulrich (DE) 2015-09-08 US disclosed
EP-2585420-A2 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION Dietz, Ulrich (DE) 2013-05-01 EP disclosed
US-20130090488-A1 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2013-04-11 US disclosed
WO-2011160857-A2 DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO- OR NANOEMULSIFICATION DIETZ ULRICH (DE) 2011-12-29 WO disclosed
EP-2399885-A1 Device and method for solubilizing, separating, removing and reacting carboxylic acids in aqueous or organic solutions by means of micro- or nanoemulsification Dietz, Ulrich (DE) 2011-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11229685-B2 Fungal iron acquisition inhibitors and uses thereof SLC40A1, SLC30A6, SLC30A7 NOS2 222/4885CYP2C19 547/4885CYP1A2 197/4885
US-20220211820-A1 FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF SLC40A1, SLC30A6, SLC30A7 NOS2 222/4885CYP2C19 547/4885CYP1A2 197/4885
US-11779634-B2 Fungal iron acquisition inhibitors and uses thereof SLC40A1, SLC30A6, SLC30A7 NOS2 222/4885CYP2C19 547/4885CYP1A2 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.